Fierce Biotech4d
Beam gene therapy for protein deficiency passes early safety test, sets efficacy bar in space: analyst
The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...
BioPharma Dive4d
Beam base editing therapy gets ‘proof of concept’ in rare lung disease
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...
Mutated DNA Restored to Normal in Gene Therapy Advance
The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation ...
Managed Healthcare Executive22h
First Clinical Proof of Genetic Mutation Correction for Rare Lung Disease
Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...
pharmaphorum4d
Beam launches $500m financing on base-editing trial data
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in ...
MedCity News5d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns ...
BioSpace3d
Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.
Dealbreaker on MSN3d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
Beam Therapeutics says CRISPR treatment shows encouraging results in lung condition
The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...
Benzinga.com5d
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
BEAM-302 showed durable, dose-dependent correction of AATD mutation in 9 patients with effects seen as early as Day 7. Beam plans further dose escalation and will report new trial data in H2 2025 ...